Filing Details

Accession Number:
0000950170-25-074323
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-05-19 16:05:22
Reporting Period:
2025-05-15
Filing Date:
2025-05-19
Accepted Time:
2025-05-19 16:05:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1609809 Seres Therapeutics Inc. MCRB Pharmaceutical Preparations (2834) 274326290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1767321 R Matthew Henn C/O Seres Therapeutics, Inc.
101 Cambridge Park Drive
Cambridge MA 02140
See Remarks No No No No
Transaction Summary
Sold: 77 shares Avg. Price: $7.28 Total Value: $560.56
Number of Shares After Transactions: 4,383 shares
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2025-05-15 140 $0.00 4,362 No 4 M Direct
Common Stock Acquisiton 2025-05-15 98 $0.00 4,460 No 4 M Direct
Common Stock Disposition 2025-05-16 77 $7.28 4,383 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2025-05-15 140 $0.00 140 $0.00
Common Stock Restricted Stock Units Disposition 2025-05-15 98 $0.00 98 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
985 No 4 M Direct
1,073 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
  2. Reflects a 1-for-20 reverse stock split effected on April 21, 2025.
  3. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on April 13, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
  4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
  5. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.